Sanofi and Regeneron downsize Kevzara’s COVID-19 test Kumar Jeetendra | April 28, 2020 Accomplices Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) have reported that – following a survey by the Independent Data Monitoring Committee (IDMC) – its examination deal with Kevzara (sarilumab) in COVID-19 will be downsized. The organizations have declared the starter results from the Phase II part of a continuous Phase II/III preliminary assessing the …
